Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Indivior and Supernus scheduled a joint conference call for August 3, 2026.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Indivior and Supernus scheduled a joint conference call for August 3, 2026
- Discussion centers on the August 1, 2026 merger agreement and related transactions
- Joint investor presentation furnished as Exhibit 99.1, providing transaction details for investors
Item EX-99.1 · Exhibit EX-99.1
- Proposed 100% stock merger with Supernus, targeted Q4 2026, subject to shareholder and regulatory approvals
- Supernus shareholders receive 1.5401 Indivior shares per share, resulting in 56.5% Indivior and 43.5% Supernus ownership
- Combined company targets $2.2B pro forma revenue, 11 medicines, and four CNS therapeutic areas
- Expected annual cost synergies of at least $125M, supporting $888M adjusted EBITDA and 41% margin
- Indivior plans a $1B pre-closing dividend funded partly by $650M assumed debt, lifting pro forma net leverage to 0.99x
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.